Successful second bone marrow transplantation in a patient with myositis ossificans progressiva and aplastic anemia.

Bone marrow transplantation has become the treatment of choice for patients with severe aplastic anemia who are fortunate enough to have allogeneic sibling donors. As patients have been transplanted earlier in the course of their disease, significant improvements have been obtained in long-term survival. However, in patients who have been sensitized by previous blood product transfusions, graft rejection continues to be a significant problem and second transplants when performed are frequently unsuccessful. This case report deals with a patient with myositis ossificans progressiva (MOP) who developed severe idiopathic aplastic anemia. He rejected his first graft after 160 days. However, he was successfully reingrafted with marrow from the same donor using a different conditioning regimen.
AuthorsW E Spruce, S J Forman, K G Blume, M J Farbstein, E P Scott, J L Wolf, R Krance
JournalThe American journal of pediatric hematology/oncology (Am J Pediatr Hematol Oncol) Vol. 5 Issue 4 Pg. 337-40 ( 1983) ISSN: 0192-8562 [Print] UNITED STATES
PMID6367519 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antilymphocyte Serum
  • Anemia, Aplastic (therapy)
  • Antilymphocyte Serum (therapeutic use)
  • Bone Marrow Transplantation
  • Child
  • Graft vs Host Disease
  • Humans
  • Leukocyte Count
  • Male
  • Myositis Ossificans (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: